| [1] |
Carlos Z，Vanesa GP，Alberto R.Obstructive sleep apnea syndrome is a systemic disease[J].Eur J Intern Med，2008，19（6）：390-398.
|
| [2] |
Li AM，So HK，Au CT，et al.Epidemiology of obstructive sleep apnoea syndrome in Chinese children：a two-phase community study[J].Thorax，2010，65（11）：991-997.
|
| [3] |
李婷，李秀翠，梁冬施.慢性间歇性低氧对大鼠肾脏氧化应激损伤及HIF-1α表达的影响[J].中国病理生理杂志，2015，31（2）：348-353.
|
| [4] |
Xie J，Wei YX，Liu S，et al.Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism[J].Chin Med J，2015，128（16）：2147-2153.
|
| [5] |
马雪，史清海，伏建峰.缺氧动物及细胞实验模型的研究进展[J].西北国防医学杂志，2016，37（8）：535-538.
|
| [6] |
Costa-Silva JH，Zoccal DB，Machado BH.Chronic intermittent hypoxia alters gluta-matergic control of sympathetic and respiratory activities in the commissural NTS of rats[J].Am J Physiol Regul Integr Comp Physiol，2012，302（6）：785-793.
|
| [7] |
Pan Z，Zhuang X，Li X，et al.Significance of vaspin in obstructive sleep apnea-hypopnea syndrome[J].Exp Ther Med，2016，11（3）：841-845.
|
| [8] |
Zhang W，Zhao ZR，Dai CF，et al.Correlation between Calpain-10 single-nucIeotide polymorphisms and obstructive sleep apnea/hypopnoea syndrome with ischemic stroke in a Chinese population：A population-based study[J].Medicine，2017，96（16）：e6570.
|
| [9] |
窦占军，王蓓，郭婧，等.氧化应激对阻塞性睡眠呼吸暂停低通气综合征肾损害的作用与抗氧化治疗现状[J].中国药物与临床，2017，17（8）：1160-1162.
|
| [13] |
Forman HJ，Torres M，Fukuto J.Redox signaling[J].Mol Cell Biochem，2002，23（4）：49-62.
|
| [14] |
Stone PH.Allopurinol a new anti-ischemic role for an old drug[J].J Am Coll Cardiol，2011，58（8）：829-830.
|
| [10] |
Chou YT，Lee PH，Yang CT.Obstructive sleep apnea：a stand alone risk factor for chronic kidney disease[J].Nephrol Dial Transplant，2011，26（7）：2244-2250.
|
| [11] |
Ma L，Zhang J，Yue L.Roles and Mechanisms of Obstructive Sleep Apnea-Hypopnea Syndrome and Chronic Intermittent Hypoxia in Atherosclerosis：Evidence and Prospective[J].Oxid Med Cell Longev，2016，2016：8215082.
|
| [12] |
Nicholl DD，Ahmed SB，Loewen AH，et al.Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia[J].Chest，2012，141（6）：1422-1430.
|
| [15] |
Xie J，Wei Y X，Liu S，et al.Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism[J].Chin Med J，2015，128（16）：2147-2153.
|
| [16] |
Ruffenach G，Chabot S，Tanguay VF，et al.Role for RUN2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension[J].Am J Respir Crit Care Med，2016，194（10）：1273-1285.
|
| [17] |
Hirsch GA，Bottomley PA，Gerstenblith G，et al.Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts[J].J Am Coll Cardiol，2012，59（9）：802-808.
|
| [18] |
Popolo A，Autore G，Pinto A，et al.Oxidative stress in patients with cardiovascular disease and chronic renal failure[J].Free Radic Res，2013，47（5）：346-356.
|
| [19] |
Saban-Ruiz J，Alonso-Pacho A，Fabregate-Fuente M，et al.Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation[J].Antiinflamm Antiallergy Agents Med Chem，2013，12（1）：94-99.
|
| [20] |
Woolf AS，Gnudi L，Long DA.Roles of angiopoietins in kidney development and disease[J].J Am Soc Nephrol，2009，20（2）：239-244.
|
| [21] |
Nurmi H，Saharinen P，Zarkada G，et al.VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption[J].EMBO Mol Med，2015，7（11）：1418-1425.
|
| [22] |
Doi K，Noiri E，Fujita T.Role of Vascular Endothelial Growth Factor in Kidney Disease[J].Curr Vasc Pharmacol，2010，8（1）：122-128.
|
| [23] |
Thurston MM，Phillips BB，Bourg CA.Safety and Efficacy of Allopurinol in Chronic Kidney Disease[J].Ann Pharmacother，2013，47（11）：1507-1516.
|
| [24] |
Muntzel M，Loera J，Coffee G，et al.Intermittent Hypoxic Challenge in Conscious Rats Elevates Heart Rate But Does Not Increase Lumbar Sympathetic Nerve Activit[J].FASEB J，2017，31（1-Suppl）：841-843.
|
